Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Byrd, John C. ^{[2
]}

Furman, Richard R. ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Benson, Don M. ^{[5
]}

Coutre, Steven E. ^{[6
]}

Kahl, Brad S. ^{[7
]}

Smith, B. Douglas ^{[8
]}

Wagner-Johnston, Nina D. ^{[9
]}

Spurgeon, Stephen E. ^{[10
]}

Giese, Neill A. ^{[11
]}

Yu, Albert S. ^{[12
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA

[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[7] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Hematol Oncol Sect, Madison, WI USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Washington Univ, Sch Med, St Louis, MO USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Calistoga Pharmaceut Inc, Seattle, WA USA

[12] Calistoga Pharmaceut, Seattle, WA USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：380 / 380

页数：1

共 50 条

[41] A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
Cohen, J.
Cordoba Mascunano, R.
Ferreri, A. J. M.
Yang, C.
Kania, M.
Kauh, J.
Ghosh, N.
ANNALS OF ONCOLOGY, 2019, 30 : 448 - 448
[42] A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
Samaniego, Felipe
Sadiq, Ahad A.
Mahadevan, Daruka
Koontz, Michael Z.
Villasboas, Jose C.
Burke, John M.
Reid, Erin G.
Cherry, Mohamad
Melear, Jason
Priego, Victor
Cobb, Patrick
Cull, Elizabeth H.
Conkling, Paul
Cosgrove, David
Roeker, Lindsey E.
Haney, Donna Nguyen
Hu, Jia
Sinha, Ranjeet Kumar
Rice, William G.
Bejar, Rafael
BLOOD, 2022, 140 : 6498 - 6500
[43] Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies
Harb, Wael A.
Diefenbach, Catherine S.
Lakhani, Nehal
Rutherford, Sarah C.
Schreeder, Marshall T.
Ansell, Stephen M.
Sher, Taimur
Aboulafia, David M.
Cohen, Jonathon B.
Nix, Darrell
Landrette, Sean
Flanders, Kate
Miller, Langdon L.
Lichenstein, Henri
Abramson, Jeremy S.
BLOOD, 2017, 130
[44] Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)
Forero-Torres, Andres
Ramchandren, Rod
Yacoub, Abdulraheem
Wertheim, Michael S.
Edenfield, William J.
Caimi, Paolo
Gutierrez, Martin
Akard, Luke
Escobar, Carolina
Call, Justin
Persky, Daniel
Iyer, Swami P.
DeMarini, Douglas J.
Zhou, Li
Yeleswaram, Swamy
Phillips, Tycel J.
BLOOD, 2017, 130
[45] A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Cheson, Bruce
Assouline, Sarit
Munir, Talha
Langerbeins, Petra
Tam, Constantine S.
Gregory, Gareth
Morschhauser, Franck
Jurczak, Wojciech
Choi, Michael
Shouse, Geoffrey
Tani, Monica
Paris, Gina
Sun, William
Atwal, Siminder
Hong, Wan-Jen
Sarkozy, Clementine
LEUKEMIA & LYMPHOMA, 2023, 64 : S48 - S48
[46] The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
Fowler, Nathan
Sharman, Jeff Porte
Smith, Sonali M.
Boyd, Thomas
Grant, Barbara
Kolibaba, Kathryn S.
Furman, Richard R.
Buggy, Joseph
Loury, David
Hamdy, Ahmed
Advani, Ranjana
BLOOD, 2010, 116 (21) : 425 - 425
[47] Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies
Qi, Junyuan
Song, Yuqin
Jiang, Bo
Li, Jianyong
Tu, Meifeng
Ping, Lingyan
Li, Zengjun
Xu, Wei
Zhu, Huayuan
Zhu, Jun
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
BLOOD, 2018, 132
[48] Results From a Phase 1/2 Study of INCB050465, a Potent and Highly Selective PI3K delta Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies
Martin, Peter
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 9 - 10
[49] Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma (vol 34, pg 2184, 2020)
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye Lim, Soon
Seog Heo, Dae
Ardeshna, Kirit
Chong, Geoffrey
Haaber, Jacob
Shi, Wei
Gorbatchevsky, Igor
Lippert, Susanne
Hiemeyer, Florian
Piraino, Paolo
Beckmann, Georg
Pena, Carol
Buvaylo, Viktoriya
Childs, Barrett H.
Salles, Gilles
LEUKEMIA, 2024, 38 (02) : 469 - 472
[50] A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)
de Vos, Sven
Schreeder, Marshall T.
Flinn, Ian W.
Coutre, Steven E.
Leonard, John P.
Wagner-Johnston, Nina D.
Fowler, Nathan H.
Boccia, Ralph V.
Barrientos, Jaqueline C.
Boyd, Thomas
Sharman, Jeff
Holes, Leanne
Lannutti, Brian
Johnson, Dave M.
Jahn, Thomas M.
Miller, Langdon L.
BLOOD, 2011, 118 (21) : 1160 - 1160

← 1 2 3 4 5 →